DGAT1 inhibitors protect pancreatic β-cells from palmitic acid-induced apoptosis

Jun-shang Huang,Bin-bin Guo,Gai-hong Wang,Li-min Zeng,You-hong Hu,Ting Wang,He-yao Wang
DOI: https://doi.org/10.1038/s41401-020-0482-7
IF: 7.169
2020-07-31
Acta Pharmacologica Sinica
Abstract:Previous studies demonstrated that prolonged exposure to elevated levels of free fatty acids (FFA), especially saturated fatty acids, could lead to pancreatic β-cell apoptosis, which plays an important role in the progression of type 2 diabetes (T2D). Diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step of triglyceride (TG) synthesis, has been reported as a novel target for the treatment of multiple metabolic diseases. In this study we evaluated the potential beneficial effects of DGAT1 inhibitors on pancreatic β-cells, and further verified their antidiabetic effects in <i>db</i>/<i>db</i> mice. We showed that DGAT1 inhibitors (<b>4a</b> and LCQ908) at the concentration of 1 μM significantly ameliorated palmitic acid (PA)-induced apoptosis in MIN6 pancreatic β-cells and primary cultured mouse islets; oral administration of a DGAT1 inhibitor (<b>4a</b>) (100 mg/kg) for 4 weeks significantly reduced the apoptosis of pancreatic islets in <i>db</i>/<i>db</i> mice. Meanwhile, <b>4a</b> administration significantly decreased fasting blood glucose and TG levels, and improved glucose tolerance and insulin tolerance in <i>db</i>/<i>db</i> mice. Furthermore, we revealed that pretreatment with <b>4a</b> (1 μM) significantly alleviated PA-induced intracellular lipid accumulation, endoplasmic reticulum (ER) stress, and proinflammatory responses in MIN6 cells, which might contribute to the protective effects of DGAT1 inhibitors on pancreatic β-cells. These findings provided a better understanding of the antidiabetic effects of DGAT1 inhibitors.
pharmacology & pharmacy,chemistry, multidisciplinary
What problem does this paper attempt to address?